» Articles » PMID: 26371143

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial

Abstract

Purpose: This multicenter study, to our knowledge, is the first phase III trial to compare trabectedin versus dacarbazine in patients with advanced liposarcoma or leiomyosarcoma after prior therapy with an anthracycline and at least one additional systemic regimen.

Patients And Methods: Patients were randomly assigned in a 2:1 ratio to receive trabectedin or dacarbazine intravenously every 3 weeks. The primary end point was overall survival (OS), secondary end points were disease control-progression-free survival (PFS), time to progression, objective response rate, and duration of response-as well as safety and patient-reported symptom scoring.

Results: A total of 518 patients were enrolled and randomly assigned to either trabectedin (n = 345) or dacarbazine (n = 173). In the final analysis of PFS, trabectedin administration resulted in a 45% reduction in the risk of disease progression or death compared with dacarbazine (median PFS for trabectedin v dacarbazine, 4.2 v 1.5 months; hazard ratio, 0.55; P < .001); benefits were observed across all preplanned subgroup analyses. The interim analysis of OS (64% censored) demonstrated a 13% reduction in risk of death in the trabectedin arm compared with dacarbazine (median OS for trabectedin v dacarbazine, 12.4 v 12.9 months; hazard ratio, 0.87; P = .37). The safety profiles were consistent with the well-characterized toxicities of both agents, and the most common grade 3 to 4 adverse effects were myelosuppression and transient elevation of transaminases in the trabectedin arm.

Conclusion: Trabectedin demonstrates superior disease control versus conventional dacarbazine in patients who have advanced liposarcoma and leiomyosarcoma after they experience failure of prior chemotherapy. Because disease control in advanced sarcomas is a clinically relevant end point, this study supports the activity of trabectedin for patients with these malignancies.

Citing Articles

Systemic Treatment in Soft Tissue Sarcomas: Are We Making a Difference?.

Paudel A, Chattopadhyay P, Rose B, Watson A, DAmato G, Trent J Cancers (Basel). 2025; 17(5).

PMID: 40075735 PMC: 11898467. DOI: 10.3390/cancers17050889.


Systemic inflammation index is a predictive and prognostic factor in patients with liposarcoma or leiomyosarcoma treated with trabectedin.

Sobczuk P, Filipowicz P, Lamparski L, Kosela-Paterczyk H, Teterycz P, Kozak K Sci Rep. 2025; 15(1):5247.

PMID: 39939795 PMC: 11821830. DOI: 10.1038/s41598-025-89977-z.


Skin and soft tissue disorders caused by trabectedin extravasation: A case report.

Matsuyama Y, Nakamura T, Yuasa H, Hagi T, Asanuma K, Hasegawa M Biomed Rep. 2025; 22(3):55.

PMID: 39926045 PMC: 11803372. DOI: 10.3892/br.2025.1933.


SEOM-GEIS Spanish clinical guidelines for the management of soft‑tissue sarcomas (2024).

Serrano C, Arregui M, Carrasco I, Hindi N, Martinez-Trufero J, Martinez-Garcia J Clin Transl Oncol. 2025; .

PMID: 39918719 DOI: 10.1007/s12094-024-03842-5.


Gemcitabine-Based Chemotherapy for Advanced Soft Tissue Sarcoma: Identifying the Appropriate Dose and Schedule.

Nakano K, Hayashi N, Wang X, Ohmoto A, Urasaki T, Fukuda N Cureus. 2025; 16(12):e76149.

PMID: 39834961 PMC: 11745528. DOI: 10.7759/cureus.76149.


References
1.
Garcia-Del-Muro X, Lopez-Pousa A, Maurel J, Martin J, Martinez-Trufero J, Casado A . Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol. 2011; 29(18):2528-33. DOI: 10.1200/JCO.2010.33.6107. View

2.
Demetri G, Chawla S, von Mehren M, Ritch P, Baker L, Blay J . Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009; 27(25):4188-96. DOI: 10.1200/JCO.2008.21.0088. View

3.
Cesne A, Blay J, Domont J, Tresch-Bruneel E, Chevreau C, Bertucci F . Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial. Lancet Oncol. 2015; 16(3):312-9. DOI: 10.1016/S1470-2045(15)70031-8. View

4.
van der Graaf W, Blay J, Chawla S, Kim D, Bui-Nguyen B, Casali P . Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012; 379(9829):1879-86. DOI: 10.1016/S0140-6736(12)60651-5. View

5.
Forni C, Minuzzo M, Virdis E, Tamborini E, Simone M, Tavecchio M . Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther. 2009; 8(2):449-57. DOI: 10.1158/1535-7163.MCT-08-0848. View